



## OPEN ACCESS

EDITED AND REVIEWED BY  
Diana Conte Camerino,  
Institut Biotechnologique de Toulouse  
(INSA), France

\*CORRESPONDENCE  
Nataschia Vedovato,  
nataschia.vedovato@dpag.ox.ac.uk

<sup>†</sup>These authors contributed equally to  
this work

SPECIALTY SECTION  
This article was submitted to  
Pharmacology of Ion Channels and  
Channelopathies,  
a section of the journal  
Frontiers in Pharmacology

RECEIVED 22 June 2022  
ACCEPTED 06 July 2022  
PUBLISHED 22 August 2022

CITATION  
Puljung M, Haythorne E, Rohm M and  
Vedovato N (2022), Editorial: Ion  
channels and transporters in diabetes  
and metabolic diseases.  
*Front. Pharmacol.* 13:975812.  
doi: 10.3389/fphar.2022.975812

COPYRIGHT  
© 2022 Puljung, Haythorne, Rohm and  
Vedovato. This is an open-access article  
distributed under the terms of the  
[Creative Commons Attribution License  
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or  
reproduction in other forums is  
permitted, provided the original  
author(s) and the copyright owner(s) are  
credited and that the original  
publication in this journal is cited, in  
accordance with accepted academic  
practice. No use, distribution or  
reproduction is permitted which does  
not comply with these terms.

# Editorial: Ion channels and transporters in diabetes and metabolic diseases

Michael Puljung<sup>1†</sup>, Elizabeth Haythorne<sup>2†</sup>, Maria Rohm<sup>3,4†</sup> and Nataschia Vedovato<sup>2\*</sup>

<sup>1</sup>Department of Chemistry and the Neuroscience Program, Trinity College, Hartford, CT, United States, <sup>2</sup>Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom, <sup>3</sup>Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany, <sup>4</sup>German Center for Diabetes Research (DZD), Neuherberg, Germany

## KEYWORDS

drug therapy, metabolic disease, repurposable drugs, membrane protein, aging, fat storage, hormone

## Editorial on the Research Topic

### Ion channels and transporters in diabetes and metabolic diseases

Textbooks frequently divide plasma membrane receptors into two distinct camps: metabotropic receptors that initiate intracellular signaling cascades in response to extracellular messengers and ionotropic receptors that exert rapid and direct effects on membrane excitability. However, rigid, this-or-that classifications cannot fully capture the bumpy landscape of plasma membrane receptors and their effects on cell signaling. Outside of textbooks, numerous ion channels and transporters serve metabotropic functions, directly impacting chemical signaling pathways (for example, via changes in intracellular  $Ca^{2+}$ ) and many are, in turn, directly activated and inhibited by changes in the concentrations of cellular messengers like cyclic nucleotides, ATP/ADP, anionic phospholipids, and inositol triphosphate. This provides a direct mechanism by which changes in electrical excitability can affect cellular/systemic metabolism and vice versa. Beyond their role coordinating potential changes in the plasma membranes of excitable cells, ion channels and transporters also influence the membranes of intracellular organelles like the endoplasmic reticulum, endosomes, lysosomes and mitochondria.

Channels and transporters set cytoplasmic and vesicular ion concentrations and pH, impact transepithelial transport, regulate cell volume, and control hormone secretion. Not surprisingly, their dysfunction impacts numerous metabolic diseases ranging from hypertension to kidney stones. The pathology and treatment of diabetes, a disease of impaired glucose homeostasis and aberrant insulin secretion, are impacted by numerous channels and transporters. The number of individuals with diabetes and metabolic diseases worldwide has risen exponentially over the last 40 years owing in part to an aging world population and epidemic rise in obesity rates. Therefore, there is a pressing need to develop more effective therapies to improve patient outcomes.

We are happy to present a collection of articles in *Frontiers in Pharmacology* highlighting ion channels and membrane transporters as new and repurposed drug targets for the treatment of metabolic disorders. The article by [Cyranka et al.](#) and review by [Armour et al.](#) identify two overlooked candidates that may help restore normal hormone secretion in diabetics. [Cyranka et al.](#) used GLUTag cells (a convenient model for enteroendocrine L-cells) to demonstrate that inhibition of NMDA-type glutamate receptors enhances secretion of the incretin hormone GLP-1, which in turn promotes insulin secretion. [Armour et al.](#) present evidence that hyperglycemia promotes Na<sup>+</sup> entry into pancreatic  $\alpha$ -cells via the Na<sup>+</sup>-coupled glucose transporter SGLT1. The increase in Na<sup>+</sup> lowers intracellular pH and disrupts energy balance, affecting normal glucagon secretion.

Closure of pancreatic ATP-sensitive K<sup>+</sup> (K<sub>ATP</sub>) channels triggers insulin secretion from pancreatic  $\beta$ -cells. K<sub>ATP</sub> inhibiting drugs like sulfonylureas and glinides have been used for decades to treat type 2 diabetes and neonatal diabetes (ND) caused by overactive K<sub>ATP</sub> channels. Unfortunately, some ND mutations are so severe that the usual drug treatments offer no relief. Furthermore, Cantú syndrome, associated with cardiovascular problems, skeletal malformations and hypertrichosis, is caused by mutations in a K<sub>ATP</sub> channel subtype that is not strongly inhibited by sulfonylureas. With this in mind, [Chen et al.](#) used extensive molecular dynamics simulations and pharmacophore modeling to identify three drugs (all in current clinical use) that inhibit K<sub>ATP</sub> channels by a direct interaction with the channel's pore. Crucially, these drugs inhibit K<sub>ATP</sub> channels bearing mutations similar to those that cause Cantú syndrome, offering some promise for the treatment of drug-resistant K<sub>ATP</sub> channelopathies.

Finally, we offer papers from [Chiang et al.](#) and [García-Casas et al.](#) that address two of the most prevalent risk factors for metabolic disorders: obesity and aging. [Chiang et al.](#) used 3T3-L1 cells to investigate the influence of P2X7 receptor activation on lipid accumulation during differentiation in adipocytes. [García-Casas et al.](#) investigated the mechanism by which the Na<sup>+</sup>/Ca<sup>2+</sup> exchanger inhibitor CGP37157 can extend the healthy lifespan of *C. elegans*.

The work presented here showcases only a sliver of the myriad connections between ion transport and metabolic disease. However, we hope that the new and reconsidered

therapies and therapeutic targets presented in this Research Topic will provoke connections, collaborations, and discoveries that may impact the millions suffering from metabolic diseases.

## Author contributions

MP, EH, and MR contributed equally. MP wrote the initial draft. All authors modified the manuscript and agreed to the final version.

## Funding

MP is supported by Trinity College start-up funds (MP). EH is supported by the UK Medical Research Council (MR/T002107/1). MR is supported by the European Research Council under the European Union's Horizon 2020 research and innovation program (# 949017), Helmholtz Association—Initiative and Networking Fund, and EFSD/Boehringer Ingelheim European Research Program on “Multi-Systems Challenges in Diabetes”. NV is supported by the UKRI Biotechnology and Biological Sciences Research Council (BB/R002517/1 and BB/R017220/1).

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.